BK
Highly rated in
35
conditions

Dr. Brad S. Kahl

Department Of Radiation Oncology
Saint Louis, MO
Highly rated in
35
conditions
Specialties:Oncology | Hematology Oncology
Experience:29 Years
Clinical Trials:Currently Recruiting for 7 Trials
Accepts:New PatientsMedicare
Highly rated in
35
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Brad S. Kahl's experience treating your condition:
About Dr. Brad S. Kahl

Brad Kahl is an Oncologist and a Hematologist Oncology expert in Saint Louis, Missouri. Kahl has been practicing medicine for over 29 years and is highly rated in 35 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Missouri. Kahl is currently accepting new patients.

His clinical research consists of co-authoring 223 peer reviewed articles and participating in 40 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Brad S. Kahl it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Brad S. Kahl accepts the following insurance:

  •  Cigna
Call to see if your plan is accepted.
Locations
5225 Mid America Plz, Saint Louis, MO 63129
Other Locations
4921 Parkview Pl, Saint Louis, MO 63110
Background & Education
Graduate Institution
Tufts University School Of Medicine, 1994
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Alton Memorial Hospital
Barnes-Jewish Hospital
Barnes-Jewish St Peters Hospital
Barnes-Jewish West County Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

40 Clinical Trials
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: August 26, 2022
Intervention Type: Biological, Drug
Study Drugs: Polatuzumab VedotinRituximabHyaluronidase HumanVenetoclax
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Recruiting
Publish Date: November 14, 2022
Intervention Type: Drug
Study Drugs: LOXO-305IbrutinibAcalabrutinibZanubrutinib
Study Phase: Phase 3
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Enrollment Status: Recruiting
Publish Date: September 01, 2022
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: August 11, 2022
Intervention Type: Biological, Drug
Study Drugs: AcalabrutinibBendamustineBendamustine HydrochlorideCytarabineRituximab
Study Phase: Phase 2
A Phase II Study Evaluating the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Untreated Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: November 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: December 14, 2022
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: ObinutuzumabVenetoclax
Study Phase: Phase 3
A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Recruiting
Publish Date: November 07, 2022
Intervention Type: Drug
Study Drug: HMPL-760
Study Phase: Phase 1
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy
Enrollment Status: Active, not recruiting
Publish Date: July 18, 2022
Intervention Type: Drug
Study Drug: Venetoclax
Study Phase: Phase 2
Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 27, 2012
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: December 05, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 1
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: March 09, 2022
Intervention Type: Drug, Biological
Study Drugs: RituximabBendamustinBortezomibLenalidomide
Study Phase: Phase 2
Identification of Biomarkers Predicting Responsiveness to Rituximab in Follicular Lymphoma
Enrollment Status: Completed
Publish Date: May 17, 2017
Intervention Type: Other, Genetic
Phase II Trial of Rituximab-CHOP (R-CHOP) Plus GM-CSF for Previously Untreated Diffuse Large Cell Lymphoma in the Elderly
Enrollment Status: Completed
Publish Date: December 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
Validating the Predictive Value (of Response to Rituximab Induction and Maintenance) of the FCGR3A 158V/F Polymorphism Using Complimentary Genotyping Methods
Enrollment Status: Completed
Publish Date: May 17, 2017
Intervention Type: Biological, Genetic, Other
A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure
Study Drugs: BendamustineRituximabCytarabinePegfilgrastimFilgrastim
Study Phase: Phase 1
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Enrollment Status: Active, not recruiting
Publish Date: April 15, 2022
Intervention Type: Procedure, Biological, Drug
Study Drugs: FludarabineCyclophosphamideALT-803Cytokine-Induced Natural Killer T CellsIL-2
Study Phase: Phase 1/Phase 2
Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: May 15, 2007
Intervention Type: Drug
Study Phase: Phase 2
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Terminated
Publish Date: April 06, 2022
Intervention Type: Combination Product, Drug
Study Phase: Phase 1/Phase 2
ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Supplemental Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab
Enrollment Status: Active, not recruiting
Publish Date: March 08, 2022
Intervention Type: Other, Dietary Supplement, Biological
Study Drugs: CholecalciferolRituximab
Study Phase: Phase 3
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active, not recruiting
Publish Date: June 27, 2022
Intervention Type: Drug
Study Drugs: ZanubrutinibBendamustineRituximabVenetoclax
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Suspended
Publish Date: December 13, 2022
Intervention Type: Drug, Biological
Study Drugs: Bendamustine HydrochlorideCyclophosphamideDoxorubicin HydrochlorideLenalidomideObinutuzumabPrednisoneUmbralisibVincristine Sulfate
Study Phase: Phase 2
Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: December 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Enrollment Status: Withdrawn
Publish Date: March 11, 2022
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: November 21, 2022
Intervention Type: Drug
Study Drugs: IxazomibIbrutinib
Study Phase: Phase 1/Phase 2
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active, not recruiting
Publish Date: December 12, 2022
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: IbrutinibObinutuzumabVenetoclax
Study Phase: Phase 3
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: September 29, 2022
Intervention Type: Biological, Procedure, Drug
Study Drugs: Personalized tumor vaccinePoly ICLCNivolumabRituximab
Study Phase: Phase 1
A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Enrollment Status: Completed
Publish Date: May 19, 2021
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: December 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Enrollment Status: Active, not recruiting
Publish Date: June 29, 2022
A Pilot Study of Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: February 04, 2022
Intervention Type: Drug, Procedure
Study Drugs: BendamustineRituximabAcalabrutinibCytarabine
Study Phase: Phase 2
Optimizing Fall-risk Prediction in Older Adults With Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Other
Ibritumomab Tiuxetan Plus Rituximab as Initial Therapy for Patients With High Tumor Burden, Indolent Histology Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: December 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
Enrollment Status: Active, not recruiting
Publish Date: November 14, 2022
Intervention Type: Drug
Study Drugs: VenetoclaxBendamustineRituximab
Study Phase: Phase 2
A Pilot Study Evaluating the Safety and Efficacy of Mosunetuzumab Consolidation Therapy After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
Enrollment Status: Not yet recruiting
Publish Date: November 09, 2022
Intervention Type: Drug
Study Phase: Phase 1
Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 24, 2022
Intervention Type: Drug
Study Drug: ABT-199 and Ibrutinib Combination
Study Phase: Phase 1
A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-cell Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: February 16, 2022
Intervention Type: Procedure
A Phase Ib Study With Expansion Cohorts Evaluating the Safety and Efficacy of Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
Enrollment Status: Not yet recruiting
Publish Date: November 23, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: December 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas
Enrollment Status: Completed
Publish Date: November 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 33 Less Clinical Trials -
223 Total Publications
A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
Journal: Leukemia & lymphoma
Published: November 02, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
RG
Dr. Ramaswamy B. Govindan
Oncology | Hematology Oncology
Highly rated in
21
conditions
Oncology
Hematology Oncology

BJC HealthCare

Center For Advanced Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 12.0 mi

Ramaswamy Govindan is an Oncologist and a Hematologist Oncology expert in Saint Louis, Missouri. Govindan has been practicing medicine for over 37 years and is highly rated in 21 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NCSLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, and Tissue Biopsy. He is licensed to treat patients in Missouri. Govindan is currently accepting new patients.

GU
Dr. Geoffrey L. Uy
Oncology | Hematology Oncology
Highly rated in
26
conditions
Oncology
Hematology Oncology

BJC HealthCare

Center For Advanced Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 12.0 mi

Geoffrey Uy is an Oncologist and a Hematologist Oncology expert in Saint Louis, Missouri. Uy has been practicing medicine for over 22 years and is highly rated in 26 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Missouri. Uy is currently accepting new patients.

JD
John F. Dipersio
Dr. John F. Dipersio
Oncology | Hematology Oncology
Highly rated in
45
conditions
Oncology
Hematology Oncology

BJC HealthCare

Center For Advanced Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 12.0 mi

John Dipersio is an Oncologist and a Hematologist Oncology expert in Saint Louis, Missouri. Dipersio has been practicing medicine for over 43 years and is highly rated in 45 conditions, according to our data. His top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Missouri. Dipersio is currently accepting new patients.